文献速递肾小球疾病慢性肾脏病

中和IL-11抗体改善Alport综合征小鼠模型肾功能并延长寿命

A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome.
PubMed 文献 · J Am Soc Nephrol · 2022-02-09

在Col4a3-/-Alport综合征小鼠模型中,随肾衰竭进展肾脏IL-11水平升高且定位于肾小管上皮细胞。中和IL-11抗体×203减少白蛋白尿、改善肾功能、减轻纤维化和炎症,并延长中位寿命44%;×203联合雷米普利使中位寿命延长99%。

要点

  • Col4a3-/-小鼠肾衰竭进展时肾脏IL-11水平升高,表达定位于肾小管上皮细胞。
  • ×203降低白蛋白尿、改善肾功能、保留足细胞数量及关键足细胞蛋白水平。
  • Col4a3-/-小鼠中位寿命:雷米普利延长22%,×203延长44%,联合延长99%。

核心结论

  • 在Alport综合征小鼠模型中,肾脏IL-11上调,中和IL-11可减少上皮-间质转化、纤维化和炎症,同时改善肾功能。
  • 抗IL-11联合ACE抑制协同延长寿命,提示靶向IL-11的治疗策略对Alport综合征进展性肾病具有前景。

研究设计与样本

  • 研究采用Col4a3-/-小鼠(缺乏编码IV型胶原成分的基因)Alport综合征模型,通过分子分析确定IL-11表达。
  • 评估中和IL-11抗体×203与IgG对照对肾小管损伤、功能、纤维化和炎症的影响。
  • 还研究了×203、IgG对照、ACE抑制剂雷米普利或雷米普利+×203对寿命的影响。

主要发现

  • Col4a3-/-小鼠随肾衰竭进展肾脏IL-11水平升高,IL-11表达定位于肾小管上皮细胞。
  • IL-11受体(IL-11RA1)表达于肾小管上皮细胞和足细胞,并在Col4a3-/-小鼠肾小管上皮细胞中上调。
  • 给予×203减少白蛋白尿、改善肾功能、保留足细胞数量及在Col4a3-/-小鼠中降低的关键足细胞蛋白水平。
  • ×203的作用伴随纤维化和炎症减少、上皮-间质转化减弱及再生标志物表达增加。
  • ×203减弱在Col4a3-/-小鼠中激活的致病性ERK和STAT3通路。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alport syndrome is a genetic disorder characterized by a defective glomerular basement membrane, tubulointerstitial fibrosis, inflammation, and progressive renal failure. IL-11 was recently implicated in fibrotic kidney disease, but its role in Alport syndrome is unknown. METHODS: We determined IL-11 expression by molecular analyses and in an Alport syndrome mouse model. We assessed the effects of a neutralizing IL-11 antibody (×203) versus an IgG control in Col4a3-/- mice (lacking the gene encoding a type IV collagen component) on renal tubule damage, function, fibrosis, and inflammation. Effects of ×203, the IgG control, an angiotensin-converting enzyme (ACE) inhibitor (ramipril), or ramipril+X203 on lifespan were also studied. RESULTS: In Col4a3-/- mice, as kidney failure advanced, renal IL-11 levels increased, and IL-11 expression localized to tubular epithelial cells. The IL-11 receptor (IL-11RA1) is expressed in tubular epithelial cells and podocytes and is upregulated in tubular epithelial cells of Col4a3-/- mice. Administration of ×203 reduced albuminuria, improved renal function, and preserved podocyte numbers and levels of key podocyte proteins that are reduced in Col4a3-/- mice; these effects were accompanied by reduced fibrosis and inflammation, attenuation of epithelial-to-mesenchymal transition, and increased expression of regenerative markers. X203 attenuated pathogenic ERK and STAT3 pathways, which were activated in Col4a3-/- mice. The median lifespan of Col4a3-/- mice was prolonged 22% by ramipril, 44% with ×203, and 99% with ramipril+X203. CONCLUSIONS: In an Alport syndrome mouse model, renal IL-11 is upregulated, and neutralization of IL-11 reduces epithelial-to-mesenchymal transition, fibrosis, and inflammation while improving renal function. Anti-IL-11 combined with ACE inhibition synergistically extends lifespan. This suggests that a therapeutic approach targeting IL-11 holds promise for progressive kidney disease in Alport syndrome.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Widjaja AA, Shekeran SG, Adami E, et al. A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome. J Am Soc Nephrol. 2022. PMID: 35140116. doi:10.1681/ASN.2021040577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。